THE SCUTTLEBUTT FEATURING ARTICLES ABOUT RESEARCHERS AT THE UNIVERSITY OF ALABAMA AT BIRMINGHAM ARE LAUNCHING A STUDY OF LOW-DOSE PSYCHEDELICS AND MORE

In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.

In today’s news:

#californiacannabis – “At its regular meeting Monday, the Healdsburg City Council preliminarily approved an end to the city’s moratorium on commercial cannabis operations, which would pave a path for two dispensaries — and potentially future consumption lounges.

The Council reached a 3-0 consensus in its first vote on the matter — a second vote will be held April 17 — with Mayor Ariel Kelley and Council member Chris Herrod absent.”

https://www.pressdemocrat.com/article/news/healdsburg-tentatively-oks-allowing-dispensaries-in-city-limits/

#psychedelics – “Researchers at the University of Alabama at Birmingham are launching a study of low-dose psychedelics as a treatment for demoralization in collaboration with a pharmaceutical company, according to a press release….

The phase two trial at UAB will explore whether the drug can help those suffering from demoralization, which is defined as feeling helpless, hopeless or lacking purpose. Principal investigator Peter Hendricks, a professor in the UAB School of Public Health, said other studies have shown that larger doses of psychedelics can help people with late-stage cancer and HIV who suffer from demoralization.

“This study aims to see if lower doses of psilocybin might treat demoralization in a broader population, that is, among those who might be experiencing demoralization for a variety of reasons, not just due to a medical condition,” Hendricks said in the press release.”

https://www.al.com/news/2023/03/alabama-university-studying-if-miscrodosing-fights-feelings-of-hopelessness.html

#cannabislaw – “A three-judge panel unanimously affirmed Detroit’s summary judgment win in the case Tuesday, rejecting the Green Genie’s claim that it had a constitutionally protected property interest in advancing to the next step of the permitting process. The opinion echoed the panel’s skepticism during oral arguments.

“As we have said before, a plaintiff may not ‘assert a property right in government procedures themselves.’ At bottom, Green Genie’s request to be heard by a special committee is little more than an interest in ‘a procedure itself, without more,'” U.S. Circuit Judge Chad A. Readler wrote.

Green Genie had claimed Detroit violated its constitutional due-process rights under the Fourteenth Amendment when a city department rejected its permit to open a medical marijuana business at the first step of review, arguing it had a right to have its application forwarded to a city committee dedicated to reviewing medical marijuana permits.”

https://www.law360.com/cannabis/articles/1588543?nl_pk=bb2d2862-9f62-42b6-ab85-0c7a674438c1&utm_source=newsletter&utm_medium=email&utm_campaign=cannabis&utm_content=2023-03-23&nlsidx=0&nlaidx=0

#CBD – “The directory includes links to the FDA’s recent actions and communications with regard to cannabidiol (CBD). Specifically, the most recent action relating to CBD was an FDA statement released in January 2023 concluding that CBD is not appropriate for the existing regulatory frameworks for foods and supplements because its use raises various safety concerns, especially with long-term use. The agency announced it would work with Congress to establish a “new way forward”.

The directory also includes a link to a webpage with links to several warning letters relating to the marketing of CBD. These letters alleged that the firms marketed unapproved new drugs which contained CBD. In addition to the potential safety concern, the agency also noted in these warning letters that under section 201(ff)(3)(B) of the Federal Food, Drug and Cosmetic Act (FFDCA), CBD products are excluded from the dietary supplement definition because the FDA is not aware of any evidence that CBD products were marketed in conventional foods or dietary supplements prior to being subject to substantial clinical investigations.”

https://www.lexology.com/commentary/healthcare-life-sciences/usa/baker-mckenzie/fda-issues-directory-to-inform-industry-and-consumers-on-dietary-supplement-ingredients-of-concern?utm_source=Lexology%2bDaily%2bNewsfeed&utm_medium=HTML%2bemail%2b-%2bPro%2bEmbed%2b-%2bGeneral%2bsection&utm_campaign=Lexology%2bsubscriber%2bdaily%2bfeed&utm_content=Lexology%2bDaily%2bNewsfeed%2b2023-03-23

Get Legal Consultation

Armada Law Corp: Excellence, Integrity, Personalized Care – Your trusted legal partner for success.